BOSTON ( TheStreet) -- Welcome to the first ever Biotech Stock Mailbag Live Chat. The floor is yours. I'm here for the next hour or so to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below. The American Society of Clinical Oncology (ASCO) meeting kicks off in a few weeks, so we can talk about hot cancer stocks like Exelixis ( EXEL), YM Biosciences ( YMI) or Dendreon ( DNDN). If you're a fan of large-cap biotech stocks, we can talk about how the emergence of oral multiple sclerosis drugs is affecting Biogen Idec ( BIIB). Celgene ( CELG) is dealing with controversy over secondary cancer risks tied to its most important drug Revlimid, so let's hash out the issue. How about discussing Amgen ( AMGN) and the pros and cons of offering its first shareholder dividend? I never shy away from controversial topics, so let's argue about the prospects for Spectrum Pharmaceuticals ( SPPI), Cell Therapeutics ( CTIC), Delcath Systems ( DCTH), Cytori Therapeutics ( CYTX) or Radient Pharmaceuticals ( RPC). New drug launches are a big investment theme in 2011, so bring your questions and comments regarding Human Genome Sciences ( HGSI), Somaxon Pharmaceuticals ( SOMX), Avanir Pharmaceuticals ( AVNR) or InterMune ( ITMN). It's your Biotech Stock Mailbag Live Chat, so let's get started. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.